Novo Nordisk Beats Challenge to Wegovy, Ozempic Obesity Patents

Novo Nordisk A/S convinced an administrative tribunal to shoot down challenges to two of its patents for the active compound in its blockbuster weight-loss drugs Ozempic and Wegovy.

The US Patent and Trademark Office’s Patent Trial and Appeal Board ruled Monday that Mylan Pharmaceuticals Inc. did not meet the requirements for an inter partes review of U.S. Patent Nos. 8,536,122 and 8,129,343. The patents encompass semaglutide, the active ingredient in the drugs, according to the PTAB’s rulings.

Mylan asserted, in seeking its review, that 12 claims of the ‘122 patent and six claims of the ‘343 patent were unpatentable in ...